$Monte Rosa Therapeutics (GLUE.US)$ 10% Shareholder Versant Venture Capital VI, L.P. sold 567.21K shares of common stock on Sep 11, 12, 13, 2024 at an average price of $6.0027 for a total value of $3.4 million.
This transaction involves other related parties: Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP, L.P. and Versant Vantage I GP-GP, LLC.
What is statement of changes in beneficial ownership of securities?
It is a requirement under federal securities laws that mandates individuals, including officers, directors, and those who hold more than 10% of any class of a company's securities (collectively known as "insiders"), to report their purchases, sales, and holdings of their company's securities by submitting Forms 3, 4, and 5.
